NICE has recommended further evidence generation for the Genedrive MT-RNR1 ID Kit, a technology developed to detect a genetic variant that guides antibiotic use and prevents hearing loss in babies.
This plan outlines the gaps in evidence for the technology and the real-world data that needs to be collected for a future NICE review. The responsibility for data collection and analysis lies with the technology developer.
Support for evidence generation will be facilitated by the Office for Life Sciences, pending business case approval. This includes funding for evidence generation consortia, bringing together analytical partners, implementation sites, and developers.
Guidance on commissioning and procurement of the technology will be provided by NHS England, who is also developing a digital health technology policy framework.
After 3 years of evidence generation, the developer should submit the evidence to NICE for review and decision making on routine adoption in the NHS.
📊 The burden of hearing loss in Africa is rising, with projections estimating that 54 million people will be affected by 2030 if no action is taken. This alarming increase highlights the urgent need for policy advocacy and improved access to ear and hearing care services.
Discover the key findings from the WHO report and the steps needed to address this pressing issue.
#SyenzaNews #HearingHealth #PublicHealth
📊 Turkey’s pharmaceutical sector is on the rise! The latest “August 2024 Foreign Trade Analysis” offers a deep dive into the performance and dynamics of foreign trade, showcasing a 3.5% increase in total exports. 🌍 Discover the insights and market trends shaping the future of the pharmaceutical industry in Türkiye.
#SyenzaNews #PharmaceuticalIndustry #TradeAnalysis #Türkiye
🌍 Celebrating a decade of **ethical collaboration** among healthcare leaders! Health Policy Watch explores the groundbreaking achievements and future directions of this international consensus. By uniting efforts, we can tackle complex health challenges more effectively.
Read more about the role of ethical collaboration in shaping global health outcomes!
#SyenzaNews #GlobalHealth #EthicalCollaboration
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
